nach oben

Calcified Tissue International

Erschienen in:

04.05.2020 | Review

Osteoarthritis: Current Molecular Biomarkers and the Way Forward

verfasst von: Virginia Byers Kraus, Morten A. Karsdal

Erschienen in: Calcified Tissue International | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

The ultimate hope of researchers and patients is a pathway to development of treatments for osteoarthritis to modify the disease process in addition to the symptoms. However, development of disease modifying drugs requires objective endpoints such as measures of joint structure, joint tissue homeostasis and/or joint survival–measures such as provided by imaging biomarkers, molecular biomarkers and joint replacement frequency, respectively. Although biomarkers supporting investigational drug use and drug approval include surrogate endpoints that may not necessarily reflect or directly correlate with the clinical outcome of interest, a formal biomarker qualification process currently exists that is a rigorous three stage process that yields biomarker approvals (or denials) for specific contexts of use. From a cost perspective, biochemical biomarkers are the ‘ones to beat’; however, even well-validated biomarkers may not cross the translation gaps for eventual use in healthcare unless they offer an advantage in terms of cost per quality adjusted life year. This review summarizes the case FOR and AGAINST biomarkers in drug development and highlights the current data for a subset of biomarkers in the osteoarthritis research field informing on cartilage homeostasis, joint inflammation and altered subchondral bone remodeling.

The Voice of the Patient: Osteoarthritis Report PC, Copenhaver C, Dernier D, Geller K, Hanson B, Harvey K, Johnson F, Kraus V, Lester G, McGrath E, Shuey D, Tuan R, Tucci A, Wyatt J (2017) Osteoarthritis patient-focused drug development: voice of the patient report. In: The voice of the patient. Arthritis Foundation, Washington, DC

Thomas D, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M (2016) Clinical development success rates 2006–2015. In: Biotechnology Innovation Organization (BIO), biomedtracker and amplion, pp 1–26

Karsdal MA, Christiansen C, Ladel C, Henriksen K, Kraus VB, Bay-Jensen AC (2014) Osteoarthritis—a case for personalized health care? Osteoarthr Cartil 22:7–16CrossRef

Bernard SA, Chelminski PR, Ives TJ, Ranapurwala SI (2018) Management of pain in the United States—a brief history and implications for the opioid epidemic. Health Serv Insights 11:1178632918819440PubMedPubMedCentral

Miller RE, Block JA, Malfait AM (2017) Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol 29:110–118PubMedPubMedCentralCrossRef

LaBranche TP, Bendele AM, Omura BC, Gropp KE, Hurst SI, Bagi CM, Cummings TR, Grantham LE 2nd, Shelton DL, Zorbas MA (2017) Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis 76:295–302PubMedCrossRef

Sand JM, Knox AJ, Lange P, Sun S, Kristensen JH, Leeming DJ, Karsdal MA, Bolton CE, Johnson SR (2015) Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res 16:69PubMedPubMedCentralCrossRef

Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC (2010) Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease? Clin Biochem 43:793–804PubMedCrossRef

Siebuhr AS, He Y, Gudmann NS, Gram A, Kjelgaard-Petersen CF, Qvist P, Karsdal MA, Bay-Jensen AC (2014) Biomarkers of cartilage and surrounding joint tissue. Biomark Med 8:713–731PubMedCrossRef

10.

Felson D, Niu J, Sack B, Aliabadi P, McCullough C, Nevitt MC (2013) Progression of osteoarthritis as a state of inertia. Ann Rheumatol Dis 72:924–929CrossRef

11.

FDA (2019) Drug development tool qualification process: transparency provisions

12.

Kraus VB, Simon LS, Katz JN, Neogi T, Hunter D, Guermazi A, Karsdal MA (2019) Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs. Osteoarthr Cartil 27:571–579. https://doi.org/10.1016/j.joca.2018.1011.1002CrossRef

13.

Kraus V, Hsueh M-F (2020) Biomarkers and Osteoarthritis. In: Ginsburg G, Willard H, Tsalik E, Woods C (eds) Genomic and Precision Medicine. Elsevier, p 429–444

14.

Karsdal MA, Krarup H, Sand JM, Christensen PB, Gerstoft J, Leeming DJ, Weis N, Schaffalitzky de Muckadell OB, Krag A (2014) Review article: the efficacy of biomarkers in chronic fibroproliferative diseases—early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 40:233–249PubMedCrossRef

15.

Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS (2015) Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr Cartil 23:1233–1241CrossRef

16.

Huang Z, Chen J, Hu QS, Huang Q, Ma J, Pei FX, Shen B, Kraus VB (2019) Meta-analysis of pain and function placebo responses in pharmacological osteoarthritis trials. Arthritis Res Ther 21:173PubMedPubMedCentralCrossRef

17.

Henriksen K, Bohren KM, Bay-Jensen AC, Karsdal MA (2010) Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? Biomarkers 15:195–204PubMedCrossRef

18.

Bay-Jensen AC, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P (2010) Biochemical markers of joint tissue turnover. Assay Drug Dev Technol 8:118–124PubMedCrossRef

19.

Zhang W, Robertson WB, Zhao J, Chen W, Xu J (2019) Emerging trend in the pharmacotherapy of osteoarthritis. Front Endocrinol 10:431CrossRef

20.

Kraus V, Vincent T (2020) Osteoarthritis. In: Goldman L, Schafer A (eds) Goldman-Cecil Medicine. Elsevier, Philadelphia, PA, pp 1698–1703

21.

Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, Christiansen C, Schubert T, Qvist P, Schett G, Platt A, Bay-Jensen AC (2011) Biochemical markers of ongoing joint damage in rheumatoid arthritis–current and future applications, limitations and opportunities. Arthritis Res Therapy 13:215CrossRef

22.

Bay-Jensen AC, Reker D, Kjelgaard-Petersen CF, Mobasheri A, Karsdal MA, Ladel C, Henrotin Y, Thudium CS (2016) Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthr Cartil 24:9–20CrossRef

23.

Huebner JL, Bay-Jensen AC, Huffman KM, He Y, Leeming DJ, McDaniel GE, Karsdal MA, Kraus VB (2014) Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis. Arthritis Rheumatol (Hoboken, NJ) 66:2440–2449CrossRef

24.

Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Brauer R, Danielsen I, Christiansen C, Qvist P, Karsdal MA (2006) Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthr Cartil 14:738–748CrossRef

25.

Kraus VB, Collins JE, Hargrove D, Losina E, Nevitt M, Katz JN, Wang SX, Sandell LJ, Hoffmann SC, Hunter DJ (2017) Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis 76:186–195PubMedCrossRef

26.

Bjerre-Bastos J, Bay-Jensen A-C, Karsdal M, Byrjalsen I, Andersen J, Riis B, Christiansen C, Bihlet A (2019) Biomarkers of bone and cartilage turnover CTX-I and CTXII predict total joint replacements in osteoarthritis. Osteoarthr Cartil 27(S31):12

27.

Luo Y, He Y, Reker D, Gudmann NS, Henriksen K, Simonsen O, Ladel C, Michaelis M, Mobasheri A, Karsdal M, Bay-Jensen AC (2018) A novel high sensitivity type II collagen blood-based biomarker, PRO-C2, for assessment of cartilage formation. Int J Mol Sci 19:3485PubMedCentralCrossRef

28.

Oganesian A, Zhu Y, Sandell LJ (1997) Type IIA procollagen amino propeptide is localized in human embryonic tissues. J Histochem Cytochem 45:1469–1480PubMedCrossRef

29.

Styrkarsdottir U, Lund SH, Thorleifsson G, Zink F, Stefansson OA, Sigurdsson JK, Juliusson K, Bjarnadottir K, Sigurbjornsdottir S, Jonsson S, Norland K, Stefansdottir L, Sigurdsson A, Sveinbjornsson G, Oddsson A, Bjornsdottir G, Gudmundsson RL, Halldorsson GH, Rafnar T, Jonsdottir I, Steingrimsson E, Norddahl GL, Masson G, Sulem P, Jonsson H, Ingvarsson T, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K (2018) Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis. Nat Genet 50:1681–1687PubMedCrossRef

30.

Tachmazidou I, Hatzikotoulas K, Southam L, Esparza-Gordillo J, Haberland V, Zheng J, Johnson T, Koprulu M, Zengini E, Steinberg J, Wilkinson JM, Bhatnagar S, Hoffman JD, Buchan N, Suveges D, Yerges-Armstrong L, Smith GD, Gaunt TR, Scott RA, McCarthy LC, Zeggini E (2019) Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet 51:230–236PubMedPubMedCentralCrossRef

31.

Luo Y, Higgins N, He Y, Byrjalsen I, Andersen J, Bihlet A, Karsdal M, Bay-Jensen A (2019) Identification of superior responders to a bone and cartilage centric treatment in osteoarthritis: low levels of cartilage formation may provide an opportunity to stimulate formation. Osteoarthr Cartil 27:S61CrossRef

32.

Hsueh MF, Onnerfjord P, Bolognesi MP, Easley ME, Kraus VB (2019) Analysis of "old" proteins unmasks dynamic gradient of cartilage turnover in human limbs. Sci Adv 5:e3203CrossRef

33.

Hunter D, Deveza L, Collins J, Losina E, Nevitt M, Roemer F, Guermazi A, Bowes M, Dam E, Eckstein F, Lynch J, Katz J, Kwoh C, Hoffman S, Kraus V (2019) Multivariable modelling of biomarker data from the phase 1 Foundation for NIH Osteoarthritis Biomarkers Consortium. Ann Rheum Dis 76:186–195

34.

Tarhan S, Unlu Z (2003) Magnetic resonance imaging and ultrasonographic evaluation of the patients with knee osteoarthritis: a comparative study. Clin Rheumatol 22:181–188PubMedCrossRef

35.

Song IH, Althoff CE, Hermann KG, Scheel AK, Knetsch T, Schoenharting M, Werner C, Burmester GR, Backhaus M (2008) Knee osteoarthritis. Efficacy of a new method of contrast-enhanced musculoskeletal ultrasonography in detection of synovitis in patients with knee osteoarthritis in comparison with magnetic resonance imaging. Ann Rheum Dis 67:19–25PubMedCrossRef

36.

Hsueh M-F, Lu Y-J, Wellman S, Bolognesi M, Kraus VB (2018) Functional folate receptor cell-associated inflammatory cytokines predict the progression of knee osteoarthritis. Osteoarthr Cartil 26(S121):228

37.

Hsueh M-F, Zhang X, Wellman S, Bolognesi M, Kraus V (2019) Synergistic roles of macrophages and neutrophils in osteoarthritis progression. Arhthritis Rheum (in review)

38.

Kraus VB, McDaniel G, Huebner JL, Stabler TV, Pieper CF, Shipes SW, Petry NA, Low PS, Shen J, McNearney TA, Mitchell P (2016) Direct in vivo evidence of activated macrophages in human osteoarthritis. Osteoarthr Cartil 24:1613–1621CrossRef

39.

Atukorala I, Kwoh CK, Guermazi A, Roemer FW, Boudreau RM, Hannon MJ, Hunter DJ (2016) Synovitis in knee osteoarthritis: a precursor of disease? Ann Rheumatol Dis 75:390–395. https://doi.org/10.1136/annrheumdis-2014-205894CrossRef

40.

Haraden CA, Huebner JL, Hsueh MF, Li YJ, Kraus VB (2019) Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation. Arthritis Res Ther 21:146PubMedPubMedCentralCrossRef

41.

Deveza LA, Kraus VB, Collins JE, Guermazi A, Roemer FW, Nevitt MC, Hunter DJ (2018) Is synovitis detected on non-contrast-enhanced magnetic resonance imaging associated with serum biomarkers and clinical signs of effusion? Data from the osteoarthritis initiative. Scand J Rheumatol 47:235–242PubMedCrossRef

42.

Huang ZY, Stabler T, Pei FX, Kraus VB (2016) Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthr Cartil 24:1769–1775CrossRef

43.

Boer CG, Radjabzadeh D, Medina-Gomez C, Garmaeva S, Schiphof D, Arp P, Koet T, Kurilshikov A, Fu J, Ikram MA, Bierma-Zeinstra S, Uitterlinden AG, Kraaij R, Zhernakova A, van Meurs JBJ (2019) Intestinal microbiome composition and its relation to joint pain and inflammation. Nat Commun 10:4881PubMedPubMedCentralCrossRef

44.

Panagopoulos PK, Lambrou GI (2018) Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications. J Musculoskel Neuronal Interact 18:304–319

45.

Siebuhr AS, Bay-Jensen AC, Leeming DJ, Plat A, Byrjalsen I, Christiansen C, van de Heijde D, Karsdal MA (2013) Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Therapy 15:R86CrossRef

46.

Gudmann NS, Junker P, Juhl P, Thudium CS, Siebuhr AS, Byrjalsen I, Karsdal MA, Bay-Jensen AC (2018) Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis. Clin Exp Rheumatol 36:829–835PubMed

47.

Kjelgaard-Petersen C, Siebuhr AS, Christiansen T, Ladel C, Karsdal M, Bay-Jensen AC (2015) Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. Biomarkers 20:547–556PubMedCrossRef

48.

Kjelgaard-Petersen CF, Platt A, Braddock M, Jenkins MA, Musa K, Graham E, Gantzel T, Slynn G, Weinblatt ME, Karsdal MA, Thudium CS, Bay-Jensen AC (2018) Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis. Arthritis Rheumatol 70:1419–1428PubMedPubMedCentralCrossRef

49.

Huang Z, Kraus VB (2016) Does lipopolysaccharide-mediated inflammation have a role in OA? Nat Rev Rheumatol 12:123–129PubMedCrossRef

50.

Goldring MB, Goldring SR (2010) Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 1192:230–237PubMedCrossRef

51.

Engbersen M, Huang Z, Kraus V (2016) Bone biomarkers related to osteoarthritis. In: Preedy V (ed) Biomarkers in disease: methods, discoveries and applications. Springer, Dordrecht, pp 1–29

52.

Chou CH, Wu CC, Song IW, Chuang HP, Lu LS, Chang JH, Kuo SY, Lee CH, Wu JY, Chen YT, Kraus VB, Lee MT (2013) Genome-wide expression profiles of subchondral bone in osteoarthritis. Arthritis Res Ther 15:R190PubMedPubMedCentralCrossRef

53.

Chou CH, Lee CH, Lu LS, Song IW, Chuang HP, Kuo SY, Wu JY, Chen YT, Kraus VB, Wu CC, Lee MT (2013) Direct assessment of articular cartilage and underlying subchondral bone reveals a progressive gene expression change in human osteoarthritic knees. Osteoarthr Cartil 21:450–461CrossRef

54.

Kraus VB, Collins JE, Charles HC, Pieper CF, Whitley L, Losina E, Nevitt M, Hoffmann S, Roemer F, Guermazi A, Hunter DJ (2018) Predictive validity of radiographic trabecular bone texture in knee osteoarthritis: the osteoarthritis research society international/foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium. Arthritis Rheumatol 70:80–87PubMedCrossRef

55.

Bettica P, Cline G, Hart DJ, Meyer J, Spector TD (2002) Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46:3178–3184PubMedCrossRef

56.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC (2017) Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 14:169–186PubMedCrossRef

57.

Collins JE, Losina E, Nevitt MC, Roemer FW, Guermazi A, Lynch JA, Katz JN, Kent Kwoh C, Kraus VB, Hunter DJ (2016) Semiquantitative Imaging Biomarkers of Knee Osteoarthritis Progression: Data From the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium. Arthritis Rheumatol (Hoboken, NJ) 68:2422–2431CrossRef

58.

Hunter D, Nevitt M, Losina E, Kraus V (2014) Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract Res 28:61–71CrossRef

59.

Kraus V, Hargrove D, Hunter D, Renner J, Jordan J (2014) Establishment of reference intervals for osteoarthritis related biomarkers—the FNIH/OARSI OA Biomarkers Consortium. Osteo Cartilage 22:podium presentation

60.

Food and Drug Administration-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource. In: FDA, Silver Spring, MD

61.

Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegard D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M (2011) Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartil 19:515–542CrossRef

62.

Kraus VB, Blanco FJ, Englund M, Henrotin Y, Lohmander LS, Losina E, Onnerfjord P, Persiani S (2015) OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 23:686–697PubMedPubMedCentralCrossRef

63.

March L, Cross M, Lo C, Arden N, Gates L, Leyland K, Hawker G, King L (2016) Osteoarthritis: a serious disease. Access Date Access 2016

Titel: Osteoarthritis: Current Molecular Biomarkers and the Way Forward
verfasst von: Virginia Byers Kraus
Morten A. Karsdal
Publikationsdatum: 04.05.2020
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 3/2021
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-020-00701-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Osteoarthritis: Current Molecular Biomarkers and the Way Forward

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Prospects for Therapies in Osteoarthritis

Models of Osteoarthritis: Relevance and New Insights

Targeting Dysregulation of Metalloproteinase Activity in Osteoarthritis

The Genetic Epidemiology of Joint Shape and the Development of Osteoarthritis

Osteoarthritis—Slow but Steady Steps Forward

The Bone Cartilage Interface and Osteoarthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Update Innere Medizin